Nivolumab reactivation of hypertrophic lichen planus, a case report and review of published literature

21Citations
Citations of this article
26Readers
Mendeley users who have this article in their library.

Abstract

We report a case of nivolumab-induced lichen planus (LP) reactivation that was previously in remission following chemotherapy for non-small-cell lung cancer (NSCLC). Chemotherapy-induced immunosuppression allowed for complete resolution of the patient’s pre-existing LP, a T-cell mediated autoimmune process. When the patient was switched to nivolumab immunotherapy owing to progression of NSCLC, PD-1 inhibition led to an overwhelming T-cell response that seemed to have provoked a severe LP reactivation. Although lichenoid reactions have been reported with nivolumab, to our knowledge, this is the first reported case of nivolumab monotherapy causing LP reactivation in a patient with a strong personal and family history of the disease that was previously in remission after chemotherapy.

Author supplied keywords

Cite

CITATION STYLE

APA

Maarouf, M., Alexander, C., & Shi, V. Y. (2018). Nivolumab reactivation of hypertrophic lichen planus, a case report and review of published literature. Dermatology Online Journal, 24(1). https://doi.org/10.5070/d3241037930

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free